Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of V118E in Healthy Participants (V118E-003)
Sponsor: Merck Sharp & Dohme LLC
Summary
Researchers are looking for new vaccines to prevent illnesses caused by a type of bacteria called Streptococcus pneumoniae. There are many different types of Streptococcus pneumoniae bacteria, called serotypes. Vaccines contain small parts of certain serotypes. These parts will not cause an infection but help the body create antibodies (proteins) to fight the bacteria. PREVNAR 20™ is a vaccine given to help to prevent disease from Streptococcus pneumoniae bacteria. Researchers designed a new vaccine, V118E, to help prevent disease from Streptococcus pneumoniae bacteria. The goal of this study is to learn how safe V118 formulation E is in Healthy Adults and how well people tolerate it.
Official title: A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V118 Formulation E in Healthy Adults
Key Details
Gender
All
Age Range
18 Years - 49 Years
Study Type
INTERVENTIONAL
Enrollment
126
Start Date
2025-10-08
Completion Date
2027-11-12
Last Updated
2026-02-27
Healthy Volunteers
Yes
Conditions
Interventions
V118E
IM administration
PREVNAR 20™
IM administration
Saline
IM administration
Locations (4)
Velocity Clinical Research, Hallandale Beach ( Site 0003)
Hallandale, Florida, United States
QPS-MRA, LLC-Early Phase ( Site 0002)
South Miami, Florida, United States
Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0004)
Springfield, Missouri, United States
University of Texas Medical Branch ( Site 0001)
Galveston, Texas, United States